Summit Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 20, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 20, 2024

SMMT$17.84+9.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 2. Properties

The following table provides information concerning Summit’s principal leased facilities as of December 31, 2023:

We maintain the following leased properties:

Type/Uses	Location	Size	Lease Expiration
Executive office	Oxfordshire, United Kingdom	6,781 square feet	February 2027
Executive office	Menlo Park, California, United States	17,760 square feet	May 2026

We signed a lease agreement on January 8, 2024 for executive office space for our new headquarters in Miami, Florida. The office space is approximately 9,000 square feet. The term of the lease is 64 months. Total payments for this office space is approximately $5,100 over the term of the lease.

We believe our facilities are suitable and adequate to meet our needs.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.